What's in the 2026 Australian Flu Vaccine — and Who's Accountable for It

What’s actually in the dose your employees receive in 2026

The 2026 Australian flu vaccine is a trivalent inactivated influenza vaccine (TIV) covering the three strains the Australian Influenza Vaccine Committee recommended and the Therapeutic Goods Administration approved for the Australian season: two influenza A subtypes (H1N1 and H3N2) and one influenza B lineage (Victoria).

The B/Yamagata lineage has not been detected in global circulation since 2020, which is why every TGA-approved formulation for the 2026 Australian season is trivalent.

Egg-based and cell-based options are both available on the Australian market; Corporate Care administers egg-based inactivated injectable TIV across all standard workplace clinics.

Corporate Care purchases the dose your employees receive through licensed Australian wholesale supply, holds it in a calibrated cold-chain kit between 2°C and 8°C from leaving the wholesaler to the moment it enters the syringe, and reports it to the Australian Immunisation Register the same day.

The vaccine itself is the easy part. The work is in the chain of custody between TGA batch release and the clinic-day chair, and in the chain of accountability that follows the dose after it’s administered.

Built and clinically led by nurses since 2010

Corporate Care was founded by Aitor Aspiazu, a Registered Nurse, in 2010. The clinical side of the business has been led by nurses ever since. Not procured from a third-party agency, not subcontracted to a clinic chain, not bolted onto a logistics company. The Registered Nurses who deliver your clinic are Corporate Care’s own people, with current AHPRA registration and HESA-accredited workplace immunisation training.

One organisation, one clinical lead, one set of standing orders that get rewritten every time a state changes the Drugs and Poisons schedule. The team who writes the consent flow is the team who runs the post-dose observation. The nurse who handled the cold-chain kit at the wholesaler is the same nurse who logs the AIR record at end of clinic.

That is the closed loop people mean when they talk about a nurse-led model — and the reason the clinical side stays largely a solved problem at our scale.

Image: Corporate Care editorial set, 2026. Trace-of-presence composition; no people depicted.

ATAGI, AIH and AIR — the three letters every workplace flu provider should follow

ATAGI is the Australian Technical Advisory Group on Immunisation. They publish the annual statement that names which population groups should receive influenza vaccination, what the dosing intervals look like, and how to handle co-administration with COVID-19 and other routine vaccines. ATAGI’s 2026 statement is the document our clinical lead reads first every February, and the document every workplace flu provider in Australia should be able to quote from on request.

The Australian Immunisation Handbook chapter 4 is where that statement becomes operational guidance: contraindications, precautions, dosing, special-risk groups, the lot. The AIH is the source the standing orders for every Australian jurisdiction defer back to. The Australian Immunisation Register is where every dose Corporate Care administers gets reported, the same day, under the mandate that has been federal law since 1 March 2021.

ATAGI says it. AIH writes it. AIR records it. A workplace flu provider that can’t hold all three letters at once is missing one of them.

Image: Corporate Care editorial set, 2026. Trace-of-presence composition; no people depicted.

The clinical edge cases we plan for, not around

Most employees in a workplace clinic walk through in two minutes. The work is in the edge cases.

Egg allergy: the Australian Immunisation Handbook position is that people with egg allergy — including a history of anaphylaxis to egg — can be safely vaccinated with any influenza vaccine, unless they have previously had a serious adverse reaction to an influenza vaccine itself. Our standing orders carry the screening prompts and the observation protocol the Handbook recommends for people with a history of anaphylaxis to egg.

Pregnancy: influenza vaccine is recommended at any trimester per the AIH; the nurse confirms gestation on the consent flow and the dose proceeds. Immunocompromised: standard inactivated influenza vaccine remains recommended; the nurse documents the underlying condition on the AIR record so the GP and treating specialist see it.

Anaphylaxis protocol travels in every clinic kit. Adrenaline auto-injectors, an in-date response plan, post-dose observation chairs set up before the first person sits down. Our nurses are trained to the rare-event response and our internal incident-review process closes the loop within twenty-four hours of anything that triggers it.

The point of a nurse-led model isn’t that edge cases never happen. It’s that when they happen, the same organisation that took the brief is the one that owns the outcome.

Operational proof the clinical model holds at scale

Approximately three thousand workplace sites in the last three years. More than one hundred thousand employees vaccinated across those sites. A Net Promoter Score averaged at 92 since 2022, from 4,400-plus survey responses.

No serious adverse-event clusters across the program in the last three years. Every incident is reviewed by the clinical lead within twenty-four hours and reported through the AIR record on the day of the dose.

The numbers aren’t the point on their own, but they answer the only question a medical director needs to ask: does the clinical model hold up when the operational side scales?

It does, and the reason it does is that the clinical model was designed by a Registered Nurse who still reads the briefs. The same person who answered the founder’s first workplace clinic in 2011 reviews the standing orders for every new state we enter. That continuity is the operational proof. Not the volume, the consistency behind it.

Last updated: 1 June 2026